Human MPL CALR BAF3 Cell Line

Description

Human MPL CALR BAF3 Cell Line is a genetically engineered model derived from the murine pro-B cell line BAF3, customized according to specific research needs. The cell line was developed through stable co-expression of exogenous human MPL (myeloproliferative leukemia virus oncogene) and mutant CALR (calreticulin) in BAF3 host cells using lentiviral vector-based transduction. Dual overexpression is validated at the transcript level by qRT-PCR.
Target
The MPL gene encodes a transmembrane receptor for thrombopoietin (TPO), primarily involved in hematopoietic stem cell maintenance and megakaryocyte differentiation via JAK-STAT signaling. Mutations in the CALR gene, often found in exon 9, result in a frameshift that produces a novel C-terminal peptide capable of aberrantly activating MPL. Co-expression of mutant CALR and MPL leads to constitutive, ligand-independent receptor activation, driving proliferation and survival of hematopoietic cells. This interaction underlies the pathogenesis of certain myeloproliferative neoplasms (MPNs), such as essential thrombocythemia and primary myelofibrosis. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.